Fresenius Medical Care Holdings, Inc. – FDA Warning Letter, Aug 6, 2010

The FDA issued a Warning Letter to Fresenius Medical Care Holdings, Inc. following a June-August 2010 inspection in Waltham, MA, citing significant violations of the Quality System (QS) regulation (21 CFR Part 820) for their kidney dialysis devices, rendering them adulterated. Concerns also extended to the firm's oversight of contract manufacturers for drug products. Key deficiencies included systemic failures in the Corrective and Preventive Action (CAPA) system (21 CFR 820.100(a), (a)(2), (a)(3), (a)(4)), such as inadequate health hazard assessments for Liberty Cassettes, uninvestigated Naturalyte Acid Concentrate labeling mix-ups, and unverified CAPA effectiveness. Complaint handling procedures were also inadequate (21 CFR 820.198(a)), with instances of voided complaints and closures without proper investigation. Critical failures in contract manufacturer oversight led to the release of Phoslo gelcaps not meeting quality specifications, including OOS stability and grease contamination. Fresenius initiated voluntary recalls and terminated the contract manufacturer. The FDA requires a written response within fifteen working days, detailing revised CAPA and risk assessment procedures with clear definitions, documentation of CAPA reviews, and plans to prevent recurrence across all manufacturing operations. Failure to promptly correct these violations could result in severe regulatory actions, including seizure, injunction, civil money penalties, and impact on federal contracts and device approvals.